LASE (LASE) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 24.6% YoY to $1,145,676, the first quarterly YoY increase of 2026; net loss narrowed 46.0% to $2,516,509, while gross margin remained negative at 39.2%.

• 9M net sales fell 33.4% to $3,867,534 and net loss increased 5.6% to $8,565,051; substantial doubt about going-concern viability remains despite improved liquidity.

• Strategy targets pharmaceutical, semiconductor, industrial and defense markets, with increasing resources for directed-energy products and Quantum Bullet development.

Financial highlights

• Q3 net sales were $1,145,676 vs. $919,284 YoY; gross loss was $449,247 vs. $433,596.

• Q3 operating expenses declined 33.9% to $1,840,594; operating loss narrowed to $2,289,841 from $3,217,000, and net loss to $2,516,509 from $4,655,608.

• 9M net sales were $3,867,534 vs. $5,808,541; operating loss increased to $7,277,776 from $5,752,528, and net loss to $8,565,051 from $8,110,233.

• 9M sales declines included lower laser-cleaning systems and services and the absence of $791,992 in prior-year affiliate revenue.

• Net interest expense declined 86% YoY following 2026 debt repayments; Q3 and 9M other expense included registration charges partly offset by derivative remeasurement gains.

Outlook and guidance

• Q4 priorities include aligning costs with sales, improving capacity utilization and sales processes, and strengthening internal controls and external reporting; no quantitative financial guidance was issued.

• Near-term goal is operating cash flow breakeven; priorities include converting the order book into deliveries and revenue and applying disciplined, gated investment to technology development.

• Quantum Bullet LSAD was planned for introduction at I/ITSEC, Nov. 30-Dec. 3, 2026; commercialization depends on further development, integration, testing and customer acceptance.

• Additional financing is expected to be needed over the next 12 months for operations and planned expenditures; management plans to assess debt and equity alternatives.